Magazine article Clinical Psychiatry News

Galantamine Shows Mixed Results for Vascular Dementia Patients

Magazine article Clinical Psychiatry News

Galantamine Shows Mixed Results for Vascular Dementia Patients

Article excerpt

SAN FRANCISCO -- The widely used anti-Alzheimer's disease drug galantamine also is effective in the treatment of patients with vascular dementia, Dr. Alexander P. Auchus said at the annual meeting of the American Academy of Neurology.

Galantamine proved significantly more effective than placebo at improving cognition and executive function in a phase III randomized clinical trial unique in that it was the first ever to employ expert MRI evaluators at a central radiology laboratory to confirm that participants indeed had vascular dementia, said Dr. Auchus of Case Western Reserve University, Cleveland.

There is at present no Food and Drug Administration-approved therapy for vascular dementia. Johnson & Johnson, sponsor of the phase III trial, doesn't intend to apply for a separate indication for galantamine in the treatment of vascular dementia, because only one of the study's two primary end points achieved statistical significance. But there is clear evidence of efficacy based upon multiple other study end points, and physicians will want to examine the data and decide for themselves whether this therapy is worth considering for their patients, the physician told this newspaper.

He reported on 788 patients diagnosed with vascular dementia by National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) criteria with MRI confirmation who were randomized to galantamine or placebo in a double-blind 26-week trial conducted at 146 sites in 21 countries. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.